## Policy Analysis Report: National Pharmaceutical Pricing Authority (NPPA) Order, December 3, 2021
**1. Executive Summary:**
This report analyzes the National Pharmaceutical Pricing Authority (NPPA) Order, dated December 3, 2021, concerning the retail price fixation of specific pharmaceutical formulations. This order fixes the retail prices of several formulations containing Dapagliflozin, Metformin, Atorvastatin, Aspirin and Ondansetron, and outlines the responsibilities of manufacturers, marketers, retailers, and dealers regarding pricing and display of price lists. This document provides an overview of the policy, its objectives, key provisions, and implications for affected stakeholders. This order is new and establishes retail prices.
**2. Introduction:**
The purpose of this report is to provide an informative analysis of the NPPA Order issued on December 3, 2021, based solely on the content of the provided policy text. The report aims to clarify the order's key provisions and implications for the pharmaceutical industry.
**3. Policy Overview:**
* **Core Objective(s):** Based on the provided text, the primary objective of this policy is to fix the retail prices of specific pharmaceutical formulations containing Dapagliflozin, Metformin, Atorvastatin, Aspirin, and Ondansetron to ensure affordability and accessibility.
**4. Background and Rationale:**
* **New Policy:** The policy likely addresses the need to regulate the pricing of essential medicines and prevent manufacturers from charging excessive prices. This ensures that these medications are accessible to the public at regulated prices. The policy is authorized under paragraphs 5, 11, and 15 of the Drugs Prices Control Order (DPCO), 2013, read with specified notifications, indicating a legislative basis for price control in the pharmaceutical sector.
**5. Key Provisions / Changes:**
* **New Policy:** The policy establishes the following key provisions:
* **Retail Price Fixation:** It specifies the retail price for each formulation (listed in column 2 of the table) based on its strength, unit, and manufacturer/marketing company (columns 3-5). The prices are listed in column 6 of the provided table.
* **Goods and Services Tax (GST):** Manufacturers may add GST to the retail price if they have actually paid it or if it is payable to the government.
* **Retail Price Calculation:** Manufacturers must determine the retail price for a pack of the formulation according to the retail price specified in the table, as per paragraph 11 of the DPCO, 2013.
* **Price List Issuance:** Manufacturers are required to issue a price list in Form V from the date of the notification, as per paragraph 24 of the DPCO, 2013, and submit it to the NPPA through IPDMS. Copies must also be sent to the State Drug Controller and dealers.
* **Price List Display:** Retailers and dealers must display the price list and any supplementary price list provided by the manufacturer conspicuously in their business premises, as per paragraph 24(4) of DPCO, 2013.
* **Applicability:** The specified retail prices apply only to the individual manufacturer/marketer who applied for price fixation/revision by submitting Form I under DPCO, 2013, and who fulfill all applicable statutory requirements.
* **Non-Compliance Penalties:** If the retail price is not complied with, the manufacturer/marketer is liable to deposit the overcharged amount along with interest under the DPCO, 2013, read with the Essential Commodities Act, 1955.
* **Supersession of Previous Orders:** The order supersedes any prior price orders fixing ceiling or retail prices for the formulations specified in column 2 of the table.
**6. Target Audience and Stakeholders:**
The policy directly affects the following stakeholders:
* **Pharmaceutical Manufacturers:** They are responsible for adhering to the fixed retail prices, issuing price lists, and ensuring compliance with the DPCO, 2013. Companies listed in column 5 of the table.
* **Marketing Companies:** Similar to manufacturers, they must comply with the pricing regulations. Companies listed in column 4 of the table.
* **Retailers and Dealers:** They are required to display price lists prominently and adhere to the specified retail prices.
* **Consumers:** They benefit from regulated prices that ensure affordability.
* **National Pharmaceutical Pricing Authority (NPPA):** The NPPA is responsible for enforcing the order and monitoring compliance.
* **State Drug Controllers:** These entities receive price lists and likely play a role in monitoring compliance within their respective states.
**7. Implementation Aspects (Inferred):**
* **Responsible Agency/Bodies:** The NPPA is the primary body responsible for implementing and enforcing the policy. State Drug Controllers also have a role in monitoring compliance.
* **Timelines/Procedures:**
* Manufacturers must issue a price list in Form V from the date of the notification (December 3, 2021).
* Manufacturers must submit the price list to the NPPA through IPDMS and provide copies to the State Drug Controller and dealers.
* Retailers and dealers must display the price list conspicuously.
* The policy does not explicitly state the time frame after the notification, it becomes effective, but it is implicit that the retail prices are to be implemented immediately after the date of notification.
**8. Expected Outcomes / Impact of Changes:**
* **Likely Intended Outcomes:** The intended outcomes of this policy include:
* **Price Control:** Stabilization and regulation of the retail prices of the specified pharmaceutical formulations.
* **Affordability:** Enhanced affordability of essential medicines for the general public.
* **Transparency:** Increased transparency in pricing through the display of price lists by retailers and dealers.
* **Compliance:** Adherence to pricing regulations by manufacturers and marketers, preventing overcharging.
**9. Conclusion:**
The NPPA Order of December 3, 2021, represents a significant effort to regulate the prices of essential pharmaceutical formulations containing Dapagliflozin, Metformin, Atorvastatin, Aspirin, and Ondansetron. By fixing retail prices and enforcing compliance, the policy aims to ensure affordability and accessibility of these medications for the public. Pharmaceutical manufacturers, marketers, retailers, and dealers must adhere to the provisions of the order to avoid penalties and contribute to a transparent and regulated pharmaceutical market.
Key Entities Referenced
NEW DELHI: Location where the order was issued.
Drugs Prices Control Order, 2013: A legal instrument that empowers the NPPA to fix the ceiling price of essential medicines
Ministry of Chemicals and Fertilizers: The Government of India ministry under which the Department of Pharmaceuticals and NPPA operate.
National Pharmaceutical Pricing Authority: A government regulatory agency responsible for fixing and revising prices of pharmaceutical products in India.
Dapagliflozin: Pharmaceutical ingredient
Metformin Hydrochloride IP: Pharmaceutical ingredient
Ms Synokem Pharmaceuticals Ltd.: Manufacturer of pharmaceutical products
Ms Panacea Biotec Pharma Ltd.: Marketing company of pharmaceutical products
Goods and Services Tax: A consumption based tax on the manufacture, sale and consumption of goods and services
Essential Commodities Act, 1955: An act of Parliament of India that was enacted to ensure the delivery of certain commodities or products to consumers at fair prices.
Atorvastatin Calcium IP: Pharmaceutical ingredient
Aspirin IP: Pharmaceutical ingredient
Ms Lupin Limited: Marketing company of pharmaceutical products
Ondansetron: Pharmaceutical ingredient
Form V: A form specified under the DPCO, 2013, used for issuing a price list of drugs.